With 0.67 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.16 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $4.875 whereas the lowest price it dropped to was $4.48. The 52-week range on STEX shows that it touched its highest point at $14.11 and its lowest point at $0.40 during that stretch. It currently has a 1-year price target of $11.00. Beta for the stock currently stands at 1.39.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of STEX was down-trending over the past week, with a drop of -2.11%, but this was down by -21.09% over a month. Three-month performance surged to 26.09% while six-month performance rose 215.65%. The stock gained 211.41% in the past year, while it has gained 318.02% so far this year. A look at the trailing 12-month EPS for STEX yields -1.06 with Next year EPS estimates of -0.04.
Float and Shares Shorts:
At present, 30.79 million STEX shares are outstanding with a float of 26.19 million shares on hand for trading. On 2025-10-15, short shares totaled 2.26 million, which was 641.9999999999999 higher than short shares on 1757894400. In addition to Mr. Ferdinand Groenewald as the firm’s Interim CFO & Principal Accounting Officer, Mr. Karl Henry McPhie serves as its CEO & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, STEX reported revenue of $0.0 and operating income of -$20365000.0. The EBITDA in the recently reported quarter was -$19806000.0 and diluted EPS was -$0.74.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. The surprise factor in the prior quarter was -$0.05.
